Published ahead of print in Nature Medicine*, the final efficacy and safety results of the ROAR basket study led by…
featured news
Published in the journal Genes & Development*, results of a study led by Laura Soucek, co-Director of the Vall d’Hebron…
Non-canonical proteins are unconventional protein products that are not part of the known protein-coding genome repertoire. They arise from unexpected…
Recently published in the Journal of Medical Genetics* results of a case-control study spearheaded by VHIO’s Judith Balmaña show that…
Futibatinib, an advanced FGFR inhibitor, has demonstrated effectiveness in impeding tumor growth among patients with FGFR-altered tumors. What is Intrahepatic…
Results of the phase II single arm, multi-site international CALYPSO study point to the efficacy of combining potent MET inhibitor…
Results of VHIO-led pharmacokinetic analysis of Omomyc, a therapeutic mini-protein that targets the MYC oncogene which is found deregulated in…
Recently published open access in the Journal for ImmunoTherapy of Cancer (1), findings from a study led by VHIO’s Alena…
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for…
The annual ASCO Symposium on Gastrointestinal Cancers took place from 19-21 January. Josep Tabernero, Director of VHIO, presented the results…
